Status:
RECRUITING
Olanzapine for Cancer Related Anorexia-cachexia Syndrome
Lead Sponsor:
Mahidol University
Conditions:
Anorexia
Cachexia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information reg...
Eligibility Criteria
Inclusion
- pathologically or cytologically metastatic or locally advanced cancer
- anorexia and \>=5% weight loss during the past 6 months or anorexia with numerical scale of anorexia \>=5
- ECOG performance status 0-3
- able to complete questionaire and able to swallow pills
Exclusion
- receiving chemotherapy or anti-cancer systemic therapy
- life expectancy longer than 1 month
- received radiotherapy at head/neck or thoracic or upper abdomen in the past 2 weeks
- surgery within 4 weeks
- pregnancy
- serum bilirubin \> 2 mg/dl or serum Cr \> 2 mg/dl
- current use of olanzapine or other antipsychotic drug
- known cardiac arrhythmia, uncontrolled brain metastasis, history of seizure or acute coronary event in the past 6 months
Key Trial Info
Start Date :
January 22 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 21 2026
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT06517199
Start Date
January 22 2024
End Date
January 21 2026
Last Update
July 24 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine Siriraj Hospital
Bangkok, Thailand, 10260
2
Division of medical oncology, department of medicine Siriraj Hospital
Bangkok, Thailand, 10700